Home » Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

September 8, 2026September 8, 2026
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff

This post was originally published on this site.

Along with several other drugmakers, Novartis has bet that lowering Lp(a) will cut the risk of sometimes fatal cardiovascular events.
bitcoin
Bitcoin (BTC) $ 79,058.00
ethereum
Ethereum (ETH) $ 2,490.31
tether
Tether (USDT) $ 0.999867
xrp
XRP (XRP) $ 1.42
bnb
BNB (BNB) $ 750.21
dogecoin
Dogecoin (DOGE) $ 0.090635
solana
Solana (SOL) $ 103.81
usd-coin
USDC (USDC) $ 0.999917
staked-ether
Lido Staked Ether (STETH) $ 2,265.05
avalanche-2
Avalanche (AVAX) $ 7.92
tron
TRON (TRX) $ 0.338907
wrapped-steth
Wrapped stETH (WSTETH) $ 2,779.67
sui
Sui (SUI) $ 0.809515
chainlink
Chainlink (LINK) $ 11.98
weth
WETH (WETH) $ 2,268.37
polkadot
Polkadot (DOT) $ 1.18